We generated two independent lines of CBA × C57BL/6 transgenic mice (strains 37 and 38) that express a dominant-negative mutant of FADD (amino acids 80-208) fused to an amino-terminal AU1 epitope tag. The mutant lacks the amino-terminal death effector domain, which is essential for recruiting and activating caspase 8 [5, 6] , and was placed under the transcriptional control of the lck proximal promoter [10] (Figure 1a) . Expression of FADD-DN in thymus and spleen was confirmed by western blotting (Figure 1b) . Both FADD-DN transgenic mouse lines showed equivalent expression levels of the mutant protein.
We generated two independent lines of CBA × C57BL/6 transgenic mice (strains 37 and 38) that express a dominant-negative mutant of FADD (amino acids 80-208) fused to an amino-terminal AU1 epitope tag. The mutant lacks the amino-terminal death effector domain, which is essential for recruiting and activating caspase 8 [5, 6] , and was placed under the transcriptional control of the lck proximal promoter [10] (Figure 1a) . Expression of FADD-DN in thymus and spleen was confirmed by western blotting (Figure 1b) . Both FADD-DN transgenic mouse lines showed equivalent expression levels of the mutant protein.
To test whether the overexpressed FADD-DN mutant was functional, we isolated thymocytes from wild-type mice and FADD-DN transgenic mice and analysed their sensitivities towards several different apoptotic stimuli. Spontaneous cell death in culture after ex vivo transplantation was unaffected in FADD-DN thymocytes (data not shown). In contrast, whereas thymocytes from control littermates were killed by stimulation of CD95 with an agonistic antibody, FADD-DN expression completely blocked apoptosis induced by anti-CD95 antibody (Figure 1c ), in accordance with previous studies [3] . These results confirmed the CD95 inhibitory effects of the transgenic FADD-DN protein and demonstrated for the first time that FADD is also required for CD95-induced apoptosis in primary cells. We next investigated whether overexpression of FADD-DN in thymocytes protected them from other pro-apoptotic stimuli. As summarised in Figure 1d , FADD-DN expression showed no detectable inhibition of apoptosis induced by UV irradiation, dexamethasone or anti-CD3 treatment when compared with wild-type thymocytes from control littermates. Thus, activation of the apoptotic pathway(s) triggered by these other stimuli is not FADD dependent, at least not in this transgenic mouse model. Several death-domain-containing members of the TNF receptor family can promote cell survival and proliferation: TNF and anti-CD95 antibody can induce proliferation in human fibroblasts [11] , and receptor activator of NF-κB (RANK), a newly-identified member of the TNF receptor family which, following interaction with its ligand, stimulates naive T-cell proliferation and can promote cytokineinduced cell survival [12] . For this reason, we examined the consequences of FADD-DN expression on T-cell activation in vitro. In the following experiments, mice from the two FADD-DN transgenic strains 37 and 38 were not further distinguished because they had behaved identically in all previous analysis. Isolated thymocytes and purified T cells from FADD-DN transgenic and from wildtype mice were stimulated in vitro with anti-CD3 and anti-CD28 antibodies and with phorbol myristate acetate (PMA) and ionomycin. FADD-DN effectively blocked the proliferative responses induced by these reagents, as determined by 3 H-thymidine incorporation (Figure 2a) . Importantly, we confirmed that the impaired thymidine incorporation was not due to loss of cell number caused by increased cell death (Table 1) : propidium iodide (PI) staining of thymocytes 24 hours after stimulation with either anti-CD3 and anti-CD28 antibodies or PMA and ionomycin showed that the same amount of cell death occurred in wild-type and FADD-DN cell populations. The inhibition of proliferation by FADD-DN was not reversed by addition of exogenous interleukin-2 (IL-2), indicating that the effect is not a consequence of impaired autocrine stimulation by IL-2 ( Figure 2a) . Together, these results suggest that overexpression of FADD-DN interferes with either proliferative or anti-cytostatic signalling from one or several death-domain-containing TNF receptor family members.
Recently, p53 has been implicated in a number of growth inhibitory signalling pathways. We were therefore interested to determine whether FADD-DN-induced growth arrest was dependent upon expression of wild-type p53. To generate p53 -/-thymocytes expressing FADD-DN, we crossed the FADD-DN mice into a p53 -/-background. Purified splenic T cells were then assayed for their proliferative response to mitogenic stimulation ( Figure 2b ). Whereas expression of FADD-DN in p53 +/+ T cells blocks proliferation when compared with wild-type p53 +/+ cells, FADD-DN exerted no inhibitory effect on proliferation in p53 -/-cells. Indeed, FADD-DN p53 -/-cells appeared to show an enhanced 3 H-thymidine incorporation compared to the wild-type p53 +/+ T cells; this increase is due to decreased apoptotic cell death in p53 -/-cultures, resulting in more viable cells being able to incorporate thymidine label ( Table 1) . The requirement for p53 in FADD-DNmediated suppression of proliferation was confirmed by flow cytometry. Cell-cycle distributions of thymocytes 24 hours after stimulation with PMA and ionomycin showed that 37% of the surviving wild-type p53 +/+ thymocytes were in S/G2 phase, compared with only 15% FADD-DN/p53 +/+ cells. In p53 -/-cells expressing FADD-DN, the number of surviving cells in S/G2 was restored to 38% (Table 1) .
Having identified the inhibitory effect of FADD-DN on proliferation in vitro, we investigated whether expression of the FADD-DN transgene exerted any influence on the growth kinetics of thymocytes in vivo. We injected transgenic and non-transgenic mice intraperitoneally with bromodeoxyuridine (BrdU) and analysed BrdU incorporation 6 hours later in isolated thymocytes by flow cytometry. As shown in Table 2 , we observed a decrease in proliferating cells in the FADD-DN transgenic mice when compared with wild-type littermates. Inhibition of BrdU incorporation was most profound in the CD4 -CD8 -double-negative (DN) thymocytes (61% reduction of cycling cells) and in the CD4 + (50% reduction) and CD8 + (22% reduction) single-positive (SP) thymocytes. These subpopulations are known to represent dividing cells in the thymus. The result was reproducible in five other in vivo labelling experiments; however, on two occasions we also observed a reduction in BrdU incorporation in the FADD-DN transgenic CD4 + CD8 + double-positive (DP) thymocytes compared to wild-type controls. We think that this difference In summary, these data establish a growth-promoting function for the death-domain-containing members of the TNF receptor family that associate with FADD during Tcell development in mice in vivo and for thymocyte and T-cell activation in vitro.
The TNF receptor homologues that contain a death domain in their cytoplasmic region and use FADD as an adaptor molecule for signalling include, at present, CD95, TNF receptor 1 (TNF-R1), p75 NGF-R, the chicken apoptosis receptor CAR1, death receptor 3 (DR3) and TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5 [13] . From the results obtained using our FADD-DN transgenic mice, it is not possible at present to single out precisely which of these receptors contribute to promotion of cell growth. The absence of any apparent proliferation defect in activated T cells derived from CD95-deficient or TNF-R1-deficient mice All experiments were performed in triplicate and repeated independently at least three times. Thymidine incorporation assays were performed according to standard protocols. T cells were purified with a mouse T-cell enrichment column kit from R&D Systems (based on a high-affinity negative selection) according to the supplier's protocol. Table 1 Effects of the absence of p53 on cell death and proliferation. Absence of p53 decreases cell death in activated T cells and abolishes inhibition of proliferation by FADD-DN. Thymocytes were stimulated with PMA and ionomycin as in Figure 2 and analysed by FACS after PI staining. The proportion of apoptotic cells represented by the sub-G1 peak was determined in the total population of cells, whereas the percentage of cycling cells (%S+G2/M) was calculated only as a proportion of the living cells. might be explained by the capacity of other TNF-R1 family receptors to substitute for both pro-apoptotic and growth-stimulating functions.
FADD-DN Control
Recently, it was shown that a dominant-negative FADD mutant can inhibit cell death but not gene induction induced by TNF receptor homologues in HeLa cells [14] . In particular, CD95-mediated activation of Jun Nterminal kinase (JNK) was unaffected suggesting that FADD-DN does not interfere with recruitment of the adaptor protein Daxx to the CD95 receptor because Daxx has been linked to the activation of JNK by CD95 [15] . It is possible that the proliferative signals that emerge from death-domain-containing receptors that use FADD are mediated either by another adaptor molecule, whose recruitment to the receptor or to another adaptor molecule like TRADD is inhibited by simultaneously binding of FADD-DN, or that the proliferation pathway bifurcates at the level of FADD itself (or even further downstream). During submission of this paper, another paper was published describing transgenic FADD-DN mice [16] . The authors observed a similar anti-proliferative effect of FADD-DN.
The p53-dependence of the growth inhibitory effect of FADD-DN is especially intriguing. A number of growth inhibitory effectors of p53 are known, and these include the p16 and p21 inhibitors of cyclin-dependent kinases [17, 18] . It will be interesting to determine whether these effectors are involved in the FADD-DN effect. 
